ACM
AXSM icon

AlphaCrest Capital Management’s Axsome Therapeutics AXSM Stock Holding History

AlphaCrest Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,268
Closed -$280K – 120
2022
Q3 		$280K Buy
+6,268
New +$313K 0.02% 1161
2020
Q2 		– Sell
-3,800
Closed -$224K – 903
2020
Q1 		$224K Buy
+3,800
New +$310K 0.03% 907

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AlphaCrest Capital Management's AXSM Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Axsome Therapeutics (AXSM) in Q4 2022, closing a stake of 6,268 shares — an estimated $280K sold.

AlphaCrest Capital Management first reported a position in AXSM in Q1 2020 and held it in 2 quarters. The position peaked at $280K in Q3 2022. 219 funds tracked by Wall St. Rank hold AXSM as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Axsome Therapeutics position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 6,268 Axsome Therapeutics shares in Q4 2022, an estimated $280K.
  • AlphaCrest Capital Management first reported a position in Axsome Therapeutics in Q1 2020 and held it in 2 quarters.
  • AlphaCrest Capital Management's Axsome Therapeutics position peaked at $280K in Q3 2022.
  • 219 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.